Trump Threatens 50% Tariff on Canadian Aircraft Amid Escalating U.S.-Canada Trade Dispute 
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Trump Administration Expands Global Gag Rule, Restricting U.S. Foreign Aid to Diversity and Gender Programs 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Trump Administration Gun Comments Spark Rift With NRA Ahead of Midterms 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Agios Pharmaceuticals has announced a major regulatory milestone with the U.S. Food and Drug Administration approving mitapivat for the treatment of anemia in adults with alpha- or beta-thalassemia. The approval represents a significant advancement for patients living with these inherited blood disorders, many of whom face lifelong complications related to chronic anemia and frequent blood transfusions.
Mitapivat, an oral therapy developed by Agios, is designed to address the underlying metabolic pathways involved in red blood cell function. The FDA’s decision was supported by strong data from Phase 3 clinical trials, which demonstrated that the treatment significantly improved hemoglobin levels in adult patients with alpha- or beta-thalassemia. In addition to increasing hemoglobin, the trials showed a meaningful reduction in transfusion burden, an outcome that could greatly improve quality of life for patients who currently depend on regular transfusions.
According to the company, mitapivat is expected to become available to eligible patients in late January 2026. This timeline reflects the need to implement a Risk Evaluation and Mitigation Strategy (REMS) program, a requirement set by the FDA to ensure the safe use of the medication. REMS programs are typically mandated when specific safety risks need to be carefully managed through monitoring, education, or controlled distribution.
While the overall clinical trial results were positive, Agios also disclosed safety findings observed during development. Five patients participating in the trials experienced adverse reactions that suggested hepatocellular injury. These cases were closely evaluated and factored into the FDA’s benefit-risk assessment, ultimately leading to the approval with additional safety oversight through the REMS program.
The FDA approval of mitapivat marks an important step forward in the treatment landscape for thalassemia-related anemia. As the first therapy of its kind approved for both alpha- and beta-thalassemia in adults, mitapivat offers new hope for reducing disease burden and improving long-term outcomes. With its upcoming launch and safety measures in place, the therapy is poised to play a key role in addressing unmet needs within the thalassemia community.
